Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
Locke JB, Pillar CM, Castanheira M, Carvalhaes CG, Andes D, Aram JA, Andrzejewski C, Bartizal K, Das AF, Sandison T, Thompson GR 3rd, Pappas PG. Locke JB, et al. Among authors: sandison t. Antimicrob Agents Chemother. 2024 May 2;68(5):e0158423. doi: 10.1128/aac.01584-23. Epub 2024 Mar 25. Antimicrob Agents Chemother. 2024. PMID: 38526046 Free PMC article. Clinical Trial.
Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR 3rd, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M, Kullberg BJ, Pullman J, Hites M, Fortún J, Horcajada JP, Kotanidou A, Das AF, Sandison T, Aram JA, Vazquez JA, Pappas PG. Thompson GR 3rd, et al. Among authors: sandison t. Lancet Infect Dis. 2024 Mar;24(3):319-328. doi: 10.1016/S1473-3099(23)00551-0. Epub 2023 Nov 23. Lancet Infect Dis. 2024. PMID: 38008099 Free article. Clinical Trial.
Treatment Outcomes Among Patients With a Positive Candida Culture Close to Randomization Receiving Rezafungin or Caspofungin in the ReSTORE Study.
Soriano A, Honore PM, Cornely OA, Chayakulkeeree M, Bassetti M, Haihui H, Dupont H, Kim YK, Kollef M, Kullberg BJ, Manamley N, Pappas P, Pullman J, Sandison T, Dignani C, Vazquez JA, Thompson GR 3rd. Soriano A, et al. Among authors: sandison t. Clin Infect Dis. 2024 Sep 26;79(3):672-681. doi: 10.1093/cid/ciae363. Clin Infect Dis. 2024. PMID: 38985561 Free PMC article. Clinical Trial.
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials.
Honoré PM, Girardis M, Kollef M, Cornely OA, Thompson GR 3rd, Bassetti M, Soriano A, Huang H, Vazquez J, Kullberg BJ, Pappas PG, Manamley N, Sandison T, Pullman J, Nseir S. Honoré PM, et al. Among authors: sandison t. Crit Care. 2024 Oct 28;28(1):348. doi: 10.1186/s13054-024-05117-5. Crit Care. 2024. PMID: 39468640 Free PMC article. Clinical Trial.
Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials.
Honoré PM, Bassetti M, Cornely OA, Dupont H, Fortún J, Kollef MH, Pappas P, Pullman J, Vazquez J, Bielicka I, Dickerson S, Manamley N, Sandison T, Thompson GR. Honoré PM, et al. Among authors: sandison t. Crit Care. 2024 Nov 11;28(1):361. doi: 10.1186/s13054-024-05152-2. Crit Care. 2024. PMID: 39529079 Free PMC article. Clinical Trial.
Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomized trials of rezafungin versus caspofungin.
Soriano A, Locke JB, Cornely OA, Roilides E, Ramos-Martinez A, Honoré PM, Castanheira M, Carvalhaes CG, Nseir S, Bassetti M, Manamley N, Sandison T, Arendrup MC. Soriano A, et al. Among authors: sandison t. Clin Microbiol Infect. 2024 Nov 22:S1198-743X(24)00560-3. doi: 10.1016/j.cmi.2024.11.029. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 39581541 Free article.
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.
Yasinskaya Y, Bala S, Waack U, Dixon C, Higgins K, Moore JN, Jjingo CJ, O'Shaughnessy E, Colangelo P, Botgros R, Nambiar S, Angulo D, Dane A, Chiller T, Hodges MR, Sandison T, Hope W, Walsh TJ, Pappas P, Katragkou A, Kovanda L, Rex JH, Marr KA, Ostrosky-Zeichner L, Sekine S, Deshpande M, Shukla SJ, Farley J. Yasinskaya Y, et al. Among authors: sandison t. Clin Infect Dis. 2023 Aug 14;77(3):380-387. doi: 10.1093/cid/ciad195. Clin Infect Dis. 2023. PMID: 37021650
37 results